REFRESH EYE ALLERGY RELIEF 0.51 %
ANTAZOLINE PHOSPHATE : 0.51 % NAPHAZOLINE HYDROCHLORIDE : 0.051 % · DIN 02315890 · ABBVIE CORPORATION
Health Canada status: CANCELLED POST MARKET
What is REFRESH EYE ALLERGY RELIEF?
REFRESH EYE ALLERGY RELIEF 0.51 % contains ANTAZOLINE PHOSPHATE : 0.51 % NAPHAZOLINE HYDROCHLORIDE : 0.051 %. It is listed in the Health Canada Drug Product Database under DIN 02315890, held by ABBVIE CORPORATION, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as cancelled post market, status dated 11-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02315890 |
|---|---|
| Brand name | REFRESH EYE ALLERGY RELIEF |
| Generic / active ingredient | ANTAZOLINE PHOSPHATE : 0.51 % NAPHAZOLINE HYDROCHLORIDE : 0.051 % |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 0.51 % |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | S01GA51 NAPHAZOLINE, COMBINATIONS |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 11-Nov-2025 |
| Original market date | 2008-08-21 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code S01GA51 NAPHAZOLINE, COMBINATIONS. 5 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLEAR EYES ALLERGY | 0.012 % | LIQUID | PRESTIGE BRANDS INC | MARKETED | DIN 02248059 |
| CLEAR EYES EXTRA STRENGTH REDNESS RELIEF | 0.50 % | SOLUTION | PRESTIGE BRANDS INC | MARKETED | DIN 02360837 |
| NAPHCON A | 0.025 % | SOLUTION | ALCON CANADA INC | MARKETED | DIN 00481408 |
| SOOTHE ALLERGY | 0.315 % | DROPS | BAUSCH & LOMB INC | MARKETED | DIN 00750794 |
| VISINE FOR ALLERGY WITH ANTIHISTAMINE | 0.025 % | DROPS | JOHNSON & JOHNSON INC | MARKETED | DIN 02242764 |
| ALBALON A | .5 % | LIQUID | ALLERGAN INC | CANCELLED POST MARKET | DIN 00433519 |
| ALLERGY EYE DROPS | 0.315 % | DROPS | BAUSCH & LOMB INC | CANCELLED POST MARKET | DIN 02394561 |
| BLUE COLLYRIUM | 0.2 MG | LIQUID | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02171937 |
| CLEAR EYES ACR BY MURINE | 0.1 MG | LIQUID | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 02232454 |
| CLEAR EYES FOR DRY EYES PLUS REDNESS RELIEF | 0.012 % | SOLUTION | PRESTIGE BRANDS INC | CANCELLED POST MARKET | DIN 02294958 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.